Premier Air Charter Strengthens Fleet with Challenger 604 Acquisition

(PinkSheets:PREM),(Pinksheets:PREM), Strategic expansion underscores commitment to growth and enhanced charter capacity, with the aircraft entering service in the coming weeks. CARLSBAD, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — Premier Air Charter Holdings Inc. (OTCID: PREM) (“Premier Air Charter,” “Premier,” “PAC,” or the “Company”) today announced the strategic addition of a Challenger 604 to its fleet, […]

Hope for PDCD Foundation Delivers Petition to FDA Urging Approval of the First Targeted PDCD Treatment

FOLSOM, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — The Hope for PDCD Foundation, a parent-led patient advocacy group dedicated to advancing research and treatments for the rare mitochondrial disease Pyruvate Dehydrogenase Complex Deficiency (PDCD), today announced that it has delivered a petition to the U.S. Food and Drug Administration urging approval of the first targeted

Stryker declares an $0.88 per share quarterly dividend

(NYSE:SYK), Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter.

ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV(TM) (Intravenously Deliverable Oncolytic Virus) platform, today announced the initiation of a first-in-human clinical trial evaluating IDOV-Immune, its investigational oncolytic vaccinia virus therapy, in patients with advanced solid tumors (NCT06910657). Additional trial sites across the United States are expected

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

(NASDAQ:ELTX), Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy 87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapy The induction

Former CIA Officer Releases Video Presentation on Global AI Threats and America’s Next Strategic Shift

Washington, D.C., Dec. 11, 2025 (GLOBE NEWSWIRE) — Former CIA officer and national security analyst Buck Sexton has officially released a video presentation examining the accelerating global Artificial Intelligence race and the strategic response now taking shape inside the United States. The presentation, which details what he calls “Manhattan 2” is now available and offers

OTC Markets Group Welcomes Grayscale Bittensor Trust (TAO) to OTCQX

(Other OTC:OTCM),(OTC US:OTCM),(Other OTC:GTAO), NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Grayscale Bittensor Trust (TAO) (OTCQX: GTAO), one of the first investment vehicles that enables investors to gain exposure to the token underlying the Bittensor

Mycom announces new AInsights capability for detection of fault correlations for higher precision in prevention of faults

Mycom, an Assurance leader offering AI, Data and Automation solutions for some of the world's largest communications service providers (CSPs), today announced its latest capability in the award-winning AI application, AInsights. https://mma.prnewswire.com/media/2842400/Mycom_New_Logo.jpg The new capability in Mycom's AInsights application offers event correlation utilizing machine learning to uncover hidden patterns in network events, analyzing historical data

Oxford Lane Capital Corp. Provides November 2025 Net Asset Value Update

(NASDAQ:OXLCO),(NasdaqGM:OXLC),(NASDAQ:OXLCP),(NASDAQ:OXLCL),(NASDAQ:OXLCZ),(NASDAQ:OXLCN),(NASDAQ:OXLCI),(NASDAQ:OXLCG), GREENWICH, Conn., Dec. 11, 2025 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) (the “Company,” “we,” or “our”) today announced the following net asset value (“NAV”) estimate as of November 30, 2025. Management's unaudited estimate of the range of

Davis & Shirtliff Named Twice in Business Worldwide Magazine’s 2025 Global Corporate Excellence Awards

Davis & Shirtliff, one of East Africa's most influential distributors of pumps, solar power systems, and water solutions, has been honoured with two prestigious awards at the Global Corporate Excellence Awards 2025. The company won “Company of the Year – Africa: Engineering Innovation in Water & Energy Solutions” and the “Sustainability & ESG Leadership Award

Scroll to Top